Imnovid (Pomalidomide) distributor
Imnovid (Pomalidomide)
Pomalidomide (marketed as Pomalyst in the U.S. and Imnovid in the EU and Russia) is a thalidomide analogue indicated, in combination with dexamethasone marketed by Celgene.
In February 2013 U.S. Food and Drug Administration (FDA) approved Pomalidomide for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
